Trial Profile
Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Mar 2017
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Glimepiride
- Indications Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms LEAD-3; LEAD-3 Mono
- Sponsors Novo Nordisk
- 14 Jul 2016 Results of a meta-analysis in African-American/black people with T2DM from seven phase III trials (NCT00395746, NCT00614120, NCT00294723, NCT00333151, NCT00331851, NCT00518882 and NCT00700817), published in the Diabetic Medicine
- 28 Mar 2011 Planned end date changed from 1 Feb 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.
- 28 Mar 2011 Planned end date changed from 1 Feb 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.